Constellation Pharmaceuticals Investor Presentation — March 2020

Document content

Stellar Science, Breakthrough Medicine

March 12, 2020Developing Next -Generation

Epigenetic Treatments for

Corporate Overview2

This presentation contains forward -looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such

forward -looking statements include, but are not limited to, the Company’s plans, strategies and prospects for its business and s tatements

regarding the development status of the Company’s product candidates, the timing of availability of clinical trial data and t he Company’s

ability to fund its operations until the second half 2022. All statements, other than statements of historical facts, contain ed in this press

release, including statements regarding the implications of preliminary or interim clinical data, the development status of t he Company’s

product candidates, and the Company’s plans for future data presentations, the Company’s strategy, future operations, future financial

position, prospects, plans and objectives of management, are forward -looking statements. The words “anticipate,” “believe,” “con tinue,”

“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would ” and similar expressions are

intended to identify forward -looking statements, although not all forward -looking statements contain these identifying words. An y forward -

looking statements are based on management’s current expectations of future events and are subject to a number of risks and u ncertainties

that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward -looking statements. These

risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to: obtain and maintain necessary approvals

from the FDA and other regulatory authorities; continue to advance its product candidates in clinical trials; whether prelimi nary or interim data

from a clinical trial will be predictive of the final results of the trial; replicate in later clinical trials positive resul ts found in preclinical studies and

early -stage clinical trials of CPI -0610, CPI -1205, and CPI -0209; advance the development of its product candidates under the tim elines it

anticipates, or at all, in current and future clinical trials; obtain, maintain, or protect intellectual property rights rela tedto its product candidates;

manage expenses; and raise the substantial additional capital needed to achieve its business objectives. CPI -0610, CPI -1205 and CPI-0209

are investigational therapies and have not been approved by the FDA (or any other regulatory authority). For a discussion of other risks and